Latest Articles
-
What To Expect From Pfizer’s Q1?
Pfizer (NYSE:PFE) is expected to publish its Q1 2019 results on April 30. This note details Trefis’ forecasts for Pfizer, as well as some of the key trends we will be watching when the company reports earnings. You can view our interactive dashb...
-
How Important Is Oncology For Pfizer?
Pfizer’s (NYSE:PFE) oncology business contributes more than 10% to its overall top line. This can be attributed to its breast cancer drug ~ Ibrance ~ which has been doing well of late, and it has a large addressable market. The contributio...
-
Pfizer’s Q4 Earnings And What Lies Ahead For The Company In 2019
Pfizer (NYSE:PFE) recently posted its Q4 results, which were slightly above the street estimates. The company’s overall sales grew 5%, while adjusted earnings per share was up 3%. As expected, the company saw higher sales for Ibrance, Eliquis, a...
-
Ibrance, Eliquis And Biosimilars Remain The Key Driver For Pfizer’s Future Earnings Growth
Pfizer (NYSE:PFE) recently posted its Q3 results, which were in line with our estimates. The company’s overall sales grew 2% while adjusted earnings per share grew 16%. As expected, the company saw higher sales for Ibrance, Eliquis, and Xeljanz,...
-
What To Expect From Pfizer’s Q3
Pfizer (NYSE:PFE) is set to report its Q3 2018 earnings on October 30, and we expect the company to post steady top line growth, primarily led by a ramp up in Ibrance sales, along with Eliquis, which has seen market share gains in the recent qua...
-
A Look At Pfizer’s Business And Outlook
Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary & Metabolism, Neuroscience, Immunology drugs, along with its Legacy Pharma, Consumer, Biosimilar & Other segment. Legacy Pharma, Cons...
-
Oncology Drugs, Eliquis And Biosimilars Will Drive Pfizer’s Future Growth
Pfizer (NYSE:PFE) recently posted its Q2 results, which were above street estimates. The company’s overall sales grew 4% while adjusted earnings per share grew 21%. As expected, the company saw higher sales for Ibrance, Eliquis, and Xeljanz, whi...
-
Ibrance, Xeljanz, And Eliquis Will Likely Drive Pfizer’s Q2 Earnings Growth
Pfizer (NYSE:PFE) is set to report its Q2 2018 earnings on July 31, and we expect the company to post steady growth, primarily led by a ramp up in Oncology drug sales. We also expect the company to benefit from Eliquis, which has been doing very...
-
Is The Market Pricing Pfizer Fairly?
We have a price estimate of $41 for Pfizer (NYSE:PFE), which is slightly above the current market price. The stock has been in the news recently after the U.S. President tweeted about the price hike for Pfizer’s drugs. The company has inc...
-
How Sensitive Is Pfizer To R&D Expense Changes?
We estimate that Pfizer’s (NYSE:PFE) R&D expenses will grow in low single digits to $7.8 billion in 2018. However, we expect a slight decline in R&D expenditure as a percentage of Pfizer’s gross profit. Of late, many large ph...
-
What Are Pfizer’s Key Sources of Revenue?
Pfizer’s (NYSE:PFE) key sources of revenues are Oncology, Neuroscience, Cardiovascular, Anti-Infectives, Musculoskeletal, and Legacy Pharma, Consumer, Biosimilars & Others. While the company’s Oncology drugs account for only 10% ...
-
Expect Oncology And Biosimilars To Drive Pfizer’s Future Growth
Pfizer (NYSE:PFE) recently posted its Q1 results, which were below street estimates. The company’s overall sales grew 1% while adjusted earnings grew 12%. While the Oncology segment did well, led by a ramp up in Ibrance sales, most of the ...
-
Pfizer Earnings Preview: Ibrance To Drive Q1 Growth
Pfizer (NYSE:PFE) is set to report its Q1 2018 earnings on May 1, and we expect the company to post steady growth, primarily led by a ramp up in Ibrance and Xeljanz sales. Both drugs have seen solid growth in recent quarters, and this trend is l...
-
How Much Is Pfizer’s Consumer Healthcare Business Worth?
Pfizer’s (NYSE:PFE) consumer healthcare business could be worth as much as $20 billion. The company has been weighing different options for its consumer healthcare business, including a spin-off or sale. In the latest update, Reckitt Benck...
-
How Will Pfizer Perform In 2018?
We have created an interactive dashboard on Pfizer’s (NYSE:PFE) expected performance in 2018. You can adjust the revenue and margin drivers to see the impact on the company’s performance. Overall, we forecast revenue growth of arou...
